RecruitingEarly Phase 1NCT06002477

Attentional Mechanisms in SCD

Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline


Sponsor

Vanderbilt University Medical Center

Enrollment

80 participants

Start Date

Mar 27, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.


Eligibility

Min Age: 55 Years

Inclusion Criteria3

  • age ≥ 55
  • Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating < 3
  • Non-smokers

Exclusion Criteria2

  • medical contraindications to the drug challenge
  • primary neurological disorder (such as stroke, epilepsy, etc.)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMecamylamine Challenge

Mecamylamine 20 mg oral pill administered once

OTHERPlacebo Comparator Challenge

Matching placebo oral pill administered once


Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06002477


Related Trials